According to a recent U.S. epidemiology study, Dravet syndrome now affects 1:15,700 newborns, 80% of whom had a SCN1A mutation. Its prevalence has doubled from the previous year. Unfortunately, many kids lack access to early diagnosis, which may have had a big impact on their quality of life and long-term development. According to the study's findings, infants who have experienced two or more protracted seizures by the age of one year should be given the option of genetic testing using an epilepsy panel.
Based on the type of treatment, distribution method, and geographic region, the Dravet Syndrome Treatment Market can be divided. The market can be broken down into anticonvulsants, benzodiazepines, vagal nerve stimulation, and other types of treatments. Hospital pharmacies, retail pharmacies, and online pharmacies are the three main distribution channels in the market.
